Search
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. … HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolase
go.drugbank.com/bio_entities/BE0004121TargetMycobacterium tuberculosisCatalyzes the hydrolysis of a carbon-carbon bond in 4,5: 9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate (4,9-DSHA) to yield 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate (DOHNAA) and
Polypeptides: 4,5:9,10-diseco-3-hydroxy-5,9,17-trioxoandrosta-1(10),2-diene-4-oate hydrolaseAncrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnAncrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.
Streptococcus pneumoniae type 8 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10326ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, Prevnar 20Streptococcus pneumoniae type 11a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10330ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, Prevnar 20Toremifene
go.drugbank.com/drugs/DB00539ApprovedInvestigational, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. … [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur (INN, BAN, USAN) is a prodrug of [DB00544] (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. … ensuring high concentrations of 5-FU at a lower dose of tegafur [L933].
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesZorecimeran
go.drugbank.com/drugs/DB15843InvestigationalThe CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))
go.drugbank.com/drugs/DB11331ApprovedWithdrawnPalmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label]. … The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.
Synonyms: PG(16:0/18:1), PG(16:0/18:1(9Z))Methadyl acetate
go.drugbank.com/drugs/DB01433ExperimentalIllicitA narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.